News & Updates

Early ivermectin use does not confer benefit for COVID-19
Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022 byAudrey Abella

In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.

Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022
Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
04 Jun 2022

Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.

Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
04 Jun 2022